BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Maleki I, Aminafshari MR, Taghvaei T, Hosseini V, Rafiei A, Torabizadeh Z, Barzin M, Orang E. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(35): 12566-12573 [PMID: 25253959 DOI: 10.3748/wjg.v20.i35.12566]
URL: https://www.wjgnet.com/1007-9327/full/v20/i35/12566.htm
Number Citing Articles
1
George N. Dalekos, Nikolaos K. Gatselis, Kalliopi Zachou, George K. Koukoulis. NAFLD and autoimmune hepatitis: Do not judge a book by its coverEuropean Journal of Internal Medicine 2020; 75: 1 doi: 10.1016/j.ejim.2020.02.001
2
Yuan Zhang, Wenjun Lu, Xiaorong Chen, Yajuan Cao, Zongguo Yang, Udayan Apte. A Bioinformatic Analysis of Correlations between Polymeric Immunoglobulin Receptor (PIGR) and Liver Fibrosis ProgressionBioMed Research International 2021; 2021: 1 doi: 10.1155/2021/5541780
3
K Kobayashi, M Suzukawa, K Watanabe, S Arakawa, S Igarashi, I Asari, A Hebisawa, H Matsui, H Nagai, T Nagase, K Ohta. Secretory IgA accumulated in the airspaces of idiopathic pulmonary fibrosis and promoted VEGF, TGF-β and IL-8 production by A549 cellsClinical and Experimental Immunology 2020; 199(3): 326 doi: 10.1111/cei.13390
4
Marialena Mouzaki, Kristin Bramlage, Ana Catalina Arce‐Clachar, Stavra A. Xanthakos. Serum Immunoglobulin A Levels Do Not Correlate With Liver Disease Severity in Pediatric Nonalcoholic Fatty Liver DiseaseJournal of Pediatric Gastroenterology and Nutrition 2018; 67(5): 631 doi: 10.1097/MPG.0000000000002104
5
David D. Odineal, M. Eric Gershwin. The Epidemiology and Clinical Manifestations of Autoimmunity in Selective IgA DeficiencyClinical Reviews in Allergy & Immunology 2020; 58(1): 107 doi: 10.1007/s12016-019-08756-7
6
Lorenz Balcar, David Bauer, Katharina Pomej, Tobias Meischl, Mattias Mandorfer, Thomas Reiberger, Michael Trauner, Bernhard Scheiner, Matthias Pinter, Michael Pavlides. Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patientsPLOS ONE 2023; 18(4): e0282680 doi: 10.1371/journal.pone.0282680
7
Yoshio Sumida, Yoshihiro Kamada, Masaki Iwai, Paul Y. Kwo, Masashi Yoneda. Diagnosis of Liver Disease2019; : 19 doi: 10.1007/978-981-13-6806-6_2
8
Versa Omrani-Nava, Iradj Maleki, Abdolrahim Ahmadi, Mahmood Moosazadeh, Akbar Hedayatizadeh-Omran, Fatemeh Roozbeh, Hasan Nahanghi, Reza Alizadeh-Navaei. Evaluation of Hepatic Enzymes Changes and Association with Prognosis in COVID-19 PatientsHepatitis Monthly 2020; 20(4) doi: 10.5812/hepatmon.103179
9
Tim Hendrikx, Martin L. Watzenböck, Sofie M. A. Walenbergh, Shahzada Amir, Sabrina Gruber, Maria Ozsvar Kozma, Heike I. Grabsch, Ger H. Koek, Marieke J. Pierik, Katharina Staufer, Michael Trauner, Satish C. Kalhan, Daisy Jonkers, Marten H. Hofker, Christoph J. Binder, Ronit Shiri-Sverdlov. Low levels of IgM antibodies recognizing oxidation-specific epitopes are associated with human non-alcoholic fatty liver diseaseBMC Medicine 2016; 14(1) doi: 10.1186/s12916-016-0652-0
10
Amirhossein Sahebkar, Elena Sancho, David Abelló, Jordi Camps, Jorge Joven. Novel circulating biomarkers for non‐alcoholic fatty liver disease: A systematic reviewJournal of Cellular Physiology 2018; 233(2): 849 doi: 10.1002/jcp.25779
11
Simiao Yu, Jingxiao Wang, Haocheng Zheng, Ruilin Wang, Nadia Johnson, Tao Li, Ping Li, Jie Lin, Yuan Li, Jin Yan, Ying Zhang, Zhenyu Zhu, Xia Ding. Pathogenesis from Inflammation to Cancer in NASH-Derived HCCJournal of Hepatocellular Carcinoma 2022; : 855 doi: 10.2147/JHC.S377768
12
Tatsuo Inamine, Bernd Schnabl. Immunoglobulin A and liver diseasesJournal of Gastroenterology 2018; 53(6): 691 doi: 10.1007/s00535-017-1400-8
13
Evan Elias, Julia Uhanova, Qian Li, Manna Zhang, Gerald Minuk. Serum immunoglobulin A levels and non-alcoholic fatty liver diseaseCanadian Liver Journal 2018; 1(4): 248 doi: 10.3138/canlivj.2018-0005